OncologyDr. Rajesh Kumar JainSurgical Oncology

Principal Director, Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi

Series overview · 12 articles

Recent Trends in Surgical Oncology

September 6, 2026

Breast cancer remains one of the commonest cancers doctors will see in practice, and getting the diagnostic sequence right, together with knowing which alternatives to reach for when a PET-CT or genomic panel is not on hand, is what actually changes outcomes for patients referred from resource-limited settings. Dr. Rajesh Kumar Jain, Principal Director of Surgical Oncology at BLK-Max Cancer Centre, New Delhi, with close to thirty years in the field, used his second Jivo Masterclass to walk through breast cancer management end to end and then field an extended, wide-ranging discussion on early detection, staging workarounds, molecular medicine and training pathways. This guide introduces a series based on that session.

A session built around the questions doctors actually face

Rather than a slide-led lecture, Dr. Jain chose an open, extempore discussion, and the questions that followed reflected the real constraints of practising oncology across sub-Saharan Africa: how to stage a cancer without a PET-CT scanner, how to recognise cancers outside breast cancer early enough to refer them while they are still curable, and how molecular tools like circulating tumour DNA and targeted therapy are starting to change what a diagnosis actually means for a patient's options.

What this series covers

This series works through the practical management of breast cancer, from diagnosis and molecular workup through treatment protocols and surgical decision-making, then moves into staging alternatives when advanced imaging is unavailable, organ-by-organ red flag symptoms for catching cancer early, two real patient cases discussed live during the session, the role of multidisciplinary tumour boards and robotic surgery in outcomes, circulating tumour DNA and cancer recurrence, personalised and immune-based treatment including CAR-T cell therapy, and how doctors can access fellowship and observership training at BLK-Max.

This article is based on a Jivo Masterclass session conducted by Dr. Rajesh Kumar Jain, Principal Director, Surgical Oncology, BLK-Max Cancer Centre, New Delhi. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording

Looking for a surgical oncology consultation or a second opinion? Get in touch with the Jivo team

This guide is based on a live Jivo Masterclass: Dr. Rajesh Kumar Jain taught doctors across Africa on September 6, 2026.

Watch the full recording, or read the guide above.

FROM THE LIVE Q&A

MO

Moderator

In sub-Saharan Africa, most countries do not have a PET-CT scanner. What alternatives can a doctor use to get a near-accurate estimation of disease stage without one?

RK

Dr. Rajesh Kumar Jain

For bone metastasis, use a nuclear bone scan; if that is unavailable, do a skeletal survey, plain X-rays of the spine, ribs, pelvis and limbs. For liver metastasis, a CT abdomen substitutes for PET, and an ultrasound is a fair investigation if CT is also unavailable. For the lungs, a CT chest is the alternative, and a plain chest X-ray is fair enough if CT is not available. Also check the uterus and ovaries with a pelvis ultrasound in every breast cancer patient, to rule out Krukenberg tumours. Ultrasound and X-rays are available almost everywhere in the world, and while less precise than PET-CT, this combination is enough to establish metastatic staging.

See all 12 questions from this masterclass →

Book a Consultation with Dr. Rajesh Kumar Jain

Book on WhatsApp

Or message us on WhatsApp: +91 98182 98669

Frequently Asked Questions

Many cancer cases referred from outside India are far advanced by the time they reach surgical oncology, with the objective becoming palliative rather than curative. How can doctors be made more aware of the need for timely referral?

Diagnosing cancer early, at stage 1 or 2, translates into cure; stage 4 offers very minimal chances of cure for any cancer. Where facilities and education are limited, the solution has three parts: awareness, awareness, and awareness, among doctors, the public and government. Over almost 30 years of practice, running thousands of community cancer-awareness camps across India, Nepal, Bhutan and Bangladesh with NGO partners has produced a real shift: around 1997, 75-80% of patients presented in stage 3 or 4; today in metropolitan India, around 60% present at an early stage.

Beyond breast cancer, where awareness is already relatively good, when should a general practitioner without easy access to specialists suspect cancers like liver, gastric or lung cancer?

A non-healing mouth ulcer of 15-20 days in a smoker warrants a biopsy for oral cancer. A voice change over six weeks or dysphagia should raise suspicion. A cough not responding to 4-5 weeks of anti-tuberculosis treatment needs a chest X-ray. Early satiety, feeling full after a much smaller meal than usual, is a classic warning sign for stomach cancer. Unexplained weight loss or easy fatiguability should raise suspicion of pancreatic or liver cancer, and every jaundice patient should get at least an ultrasound rather than being assumed to have hepatitis. A change in bowel habit should prompt investigation for colorectal cancer, and around 30% of bleeding per rectum, usually assumed to be piles, is actually cancer. A painless testicular swelling should not be assumed to be a hydrocele without an ultrasound, and an enlarging soft tissue lump assumed to be a lipoma should get an FNAC to rule out sarcoma.

A patient case from Dr. Alem in Ethiopia: right breast masses, two in number near the periareolar region, 3cm and 4cm, attached to each other by fibrous tissue, with core needle biopsy showing invasive ductal carcinoma. How should this proceed, and is breast conservation surgery possible?

Complete staging first, chest X-ray, abdominal ultrasound and a skeletal survey or bone scan, to know whether there is metastasis. If there is no distant metastasis and ER/PR is positive, go for surgery, but because this is periareolar, central-quadrant disease, mastectomy with axillary clearance is the better option over breast conservation, even if the rest of the breast looks normal on mammography. If metastasis is found instead, start with chemotherapy.

A question from Dr. Isaya Mhando in Tanzania, based on a patient seen five years ago: what are the causes of bloody discharge from the breast, with no breast lump and no palpable lymph nodes?

There are three common causes. Duct papilloma is the most common, a benign lesion that can sometimes transform into papillary carcinoma; ultrasound will show the ducts, and if a papilloma is found, a microdochectomy (removal of the duct under image guidance) is done and sent for histopathology. Invasive ductal carcinoma itself is the second cause; around 10% of breast cancer patients present with nipple discharge, sometimes without any lump. The third is duct ectasia, seen in perimenopausal women around 45-57 years old, usually with brownish discharge, treated the same way with a microdochectomy.

How does treatment at an advanced facility like BLK-Max, compared to a tier-city setup, actually change patient outcomes, including timely referral and cost, in a way that helps doctors counsel patients?

The same operation done as open surgery might mean about ten days of recovery, while a robotic approach can have a patient back to work in three or four days, with less pain and lower rates of bleeding and infection, even when the cure rate is comparable. Where next-generation gene sequencing is available, a lung adenocarcinoma patient can sometimes be managed with a single daily tablet instead of radiation, chemotherapy or surgery. For complex cases with no standard guideline, such as a pregnant patient with ovarian cancer, a full multidisciplinary tumour board, pathologist, radiologist, surgical oncologist, medical oncologist, radiation oncologist and social worker, arrives at a genuinely joint decision rather than each specialist pushing their own preferred treatment.

What does this masterclass series cover?

Breast cancer diagnosis, staging and treatment, surgical decision-making, cancer staging alternatives when PET-CT is unavailable, organ-by-organ red flag symptoms for early detection, two real patient case discussions, multidisciplinary cancer care, circulating tumour DNA, personalised and immune-based treatment, and fellowship training opportunities.

Who is Dr. Rajesh Kumar Jain?

Principal Director, Surgical Oncology at BLK-Max Cancer Centre, New Delhi, with 29.5 years of practice across breast, head and neck, thoracic, gastrointestinal, urogenital, gynaecological, soft tissue and bone cancers.

Need Expert Medical Guidance?

Connect with leading specialists through the Jivo Healthcare network for personalized advice.

Get Expert Opinion